Arrowhead Research | ARWR - Sales Revenues


Arrowhead Research reported $75.23M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.52B 112M Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
TG Therapeutics USD 259.94M 19.6M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026